BractonDeal Intel
Get full access
AcquisitionFinTech

Mirum Pharmaceuticals, Inc. acquired Bile Acid Product Portfolio

Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.

Deal tape row

Mirum Pharmaceuticals, Inc. -> Bile Acid Product Portfolio · $445 million

Under the terms of the definitive agreement, Mirum will purchase Travere’s bile acid product portfolio for $445 million, consisting of $210 million upfront and $235 million in potential sales-based milestone payments.

Open source record (SEC) ↗